Phio Pharmaceuticals Corp. announced on March 5, 2025, the successful completion of the required enrollment for safety in its third dose cohort of the PH-762 Phase 1b dose-escalating clinical study. This milestone marks significant progress in the clinical development of its lead compound, PH-762.
The company plans to initiate screening of the fourth dose cohort in early April. The Phase 1b study (NCT 06014086) is a multi-center trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Robert Bitterman, CEO of Phio Pharmaceuticals, expressed excitement with the rapid completion of enrollment. He stated that the company looks forward to rapidly advancing the study to bring an innovative, alternative treatment option to patients with skin carcinomas, underscoring the importance of this operational achievement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.